TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23462343

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle intervention delivered via group classes and individual motivational interviewing sessions
Number of subjects: 250

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle intervention
Number of subjects: 250
Study: 22146172

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (4 training sessions)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 26
Study: 19762512

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17330831

Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15129980

Group type: EXPERIMENTAL
Intervention: Vaginal clotrimazole cream
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Test gel product
Number of subjects: 8
Study: 11556579

Group type: EXPERIMENTAL
Intervention: Single dose of albendazole 400 mg (A1, n=34)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 3 days of albendazole 400 mg daily (A3, n=34)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 5 days of albendazole 400 mg daily (A5, n=35)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Single dose of albendazole 400 mg plus praziquantel 40 mg/kg (AIP1, n=34)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 3 days of albendazole 400 mg plus praziquantel 40 mg/kg daily (A3P3, n=36)
Number of subjects: 173
Study: 9563866

Group type: EXPERIMENTAL
Intervention: TIVA using propofol with alfentanil (high infusion rate)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: TIVA using propofol with alfentanil (low infusion rate)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sodium thiopentone induction and inhalational maintenance (isoflurane)
Number of subjects: 73
Study: 7910733

Group type: EXPERIMENTAL
Intervention: Rapid Eye Movement Desensitization (REMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow Eye Movement Desensitization (SEMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stationary-Imagery (SI)
Number of subjects: 0
Study: 3306994

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Piperacillin and Clindamycin and Gentamicin
Number of subjects: 63
Study: 30365428

Group type: EXPERIMENTAL
Intervention: Do then See
Number of subjects: 36

Group type: COMPARATOR
Intervention: See then Do
Number of subjects: 36
Study: 30634206

Group type: EXPERIMENTAL
Intervention: WM + HD group (60 cases)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western medicine group (60 cases)
Number of subjects: 120
Study: 24710341

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Discontinuation of CPAP therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AutoCPAP
Number of subjects: 80
Study: 22727324

Group type: EXPERIMENTAL
Intervention: Ergonomics Trained
Number of subjects: 22

Group type: COMPARATOR
Intervention: Minimally Trained
Number of subjects: 22
Study: 20707248

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) group: hyperbaric bupivacaine 15 mg plus 100 mcg of preservative-free morphine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Single-shot ultrasound-guided femoral nerve block (FNB) group: ropivacaine 0.75% 25 ml
Number of subjects: 52
Study: 18387655

Group type: EXPERIMENTAL
Intervention: 40% fat-based diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30% fat-based diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal activity after six weeks
Number of subjects: 20
Study: 16857890

Group type: EXPERIMENTAL
Intervention: NREM delta power density (DPD)
Number of subjects: 69
Study: 12807337

Group type: EXPERIMENTAL
Intervention: EPs 7630 (30 drops three times daily for 7 days)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (30 drops three times daily for 7 days)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 12024594

Group type: EXPERIMENTAL
Intervention: Intravascular low level He‐Ne laser irradiation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 58
Study: 8865711

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 0.5% isoflurane, nitrous oxide and oxygen supplemented with epidural analgesia
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: General anesthesia with isoflurane, nitrous oxide and oxygen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with 0.5% isoflurane, nitrous oxide, oxygen and intravenous fentanyl
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 1510899

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam administered in conscious sedation doses
Number of subjects: 20
Study: 6084856

Group type: COMPARATOR
Intervention: Irradiation alone (35 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiation (30 Gy) and bleomycin (5 mg i.m. 1/2‐1 h before each irradiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiation alone (63 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiation (55 Gy) and bleomycin (5 mg i.m. 1/2‐1 h before each irradiation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleomycin and adriamycin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation with or without bleomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irradiation with or without bleomycin in operable patients
Number of subjects: 0
Study: 30626264

Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not available)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (specific control details not available)
Number of subjects: 319
Study: 30542024

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 450
Study: 26634942

Group type: EXPERIMENTAL
Intervention: Intravaginal 0.50% (6.5 mg) DHEA administered daily for 12 weeks
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo administered daily for 12 weeks
Number of subjects: 373
Study: 25283469

Group type: EXPERIMENTAL
Intervention: Composite of 5 daily pain intensity ratings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single daily pain intensity rating
Number of subjects: 0
Study: 22033702

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (off PPI)
Number of subjects: 40
Study: 18807079

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) measurement before orthodontic treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) measurement after orthodontic treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interpretable PTT signal during apnea
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pre-treatment status
Number of subjects: 8

Group type: COMPARATOR
Intervention: Type of apnea
Number of subjects: 8

Group type: COMPARATOR
Intervention: Duration of apnea
Number of subjects: 8
Study: 17241859

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15896617

Group type: EXPERIMENTAL
Intervention: OnP-BH
Number of subjects: 40

Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 40
Study: 12789992

Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide gel (Colgate Simply White Clear Whitening Gel) applied twice daily after brushing with a nonwhitening dentifrice
Number of subjects: 80

Group type: COMPARATOR
Intervention: Commercially available whitening dentifrice used twice daily for brushing
Number of subjects: 80
Study: 9583844

Group type: EXPERIMENTAL
Intervention: 25 mg ascorbic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mg ascorbic acid
Number of subjects: 20
Study: 7633987

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Analgesic treatment (control)
Number of subjects: 51
Study: 2144216

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 190970

Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 374
Study: 31596044

Group type: EXPERIMENTAL
Intervention: LARIAT group
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study: 29136625

Group type: EXPERIMENTAL
Intervention: Fluoridated salt (250 mg F-/kg salt) used in meals for the intervention group
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (no fluoridated salt used in meals)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Fluoridated salt intervention
Number of subjects: 441
Study: 25834206

Group type: EXPERIMENTAL
Intervention: Integral-based hatha yoga (2 classes of 60 minutes each and 1 home practice per week for 8 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study: 23233657

Group type: EXPERIMENTAL
Intervention: Thalidomide (50 mg daily for 2 years)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bortezomib maintenance
Number of subjects: 96
Study: 22159782

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (retinol, β‐carotene, α‐tocopherol, ascorbic acid, selenium)
Number of subjects: 274
Study: 19902288

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical control arm
Number of subjects: 0
Study: 17872899

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy in ER-negative/PrPc-positive disease
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy in ER-negative/PrPc-negative tumors
Number of subjects: 756
Study: 15480326

Group type: EXPERIMENTAL
Intervention: Coseasonal sublingual immunotherapy (SLIT) for 3 years
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard symptomatic therapy (control)
Number of subjects: 113
Study: 11568050

Group type: EXPERIMENTAL
Intervention: Coarctation patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 64
Study: 9764616

Group type: EXPERIMENTAL
Intervention: Mifepristone (400 mg orally)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 7919903

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion (GIK)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (R)
Number of subjects: 40
Study: 2837991

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day b.i.d. combined with FT‐207 600 mg/day t.i.d.
Number of subjects: 0
Study: 31988343

Group type: EXPERIMENTAL
Intervention: Affinity-matured variants of nimotuzumab (K4 and K5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nimotuzumab (original)
Number of subjects: 0
Study: 31174946

Group type: EXPERIMENTAL
Intervention: AffinosÂ®
Number of subjects: 34

Group type: COMPARATOR
Intervention: OSferionÂ® (control group)
Number of subjects: 34
Study: 28961815

Group type: EXPERIMENTAL
Intervention: Routine antibiotic prescription monitoring and feedback based on health insurance claims data
Number of subjects: 250
Study: 26616809

Group type: EXPERIMENTAL
Intervention: IMA high ligation group (63 cases, cutting distance of 1.0 to 1.5 cm to the root of IMA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: IMA low ligation group (65 cases, cutting distance of 0.5 to 1.0 cm to the root of left colic artery)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: IMA high ligation group
Number of subjects: 128

Group type: COMPARATOR
Intervention: IMA low ligation group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study: 22903141

Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT); performed twice within 2 weeks; main outcome: Peak Work Rate (WRpeak)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Regular Cardiopulmonary Exercise Test (CPET) with respiratory gas analysis; performed within 2 weeks; main outcome: Peak Oxygen Uptake (VO2peak)
Number of subjects: 75
Study: 21483491

Group type: EXPERIMENTAL
Intervention: Standard ART (≤4 ARVs)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Intensive ART (≥5 ARVs)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Immediate retreatment initiation
Number of subjects: 368

Group type: COMPARATOR
Intervention: Interruption before re‐treatment
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Re‐treatment options
Number of subjects: 368
Study: 19483372

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (3 times per week for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 16765793

Group type: EXPERIMENTAL
Intervention: cyclosporine 0.05% ophthalmic emulsion
Number of subjects: 21

Group type: COMPARATOR
Intervention: unpreserved artificial tears
Number of subjects: 21
Study: 14756932

Group type: EXPERIMENTAL
Intervention: Dependents (18)
Number of subjects: 100
Study: 11087764

Group type: EXPERIMENTAL
Intervention: IVIg (0.4 g/kg/d for 5 consecutive days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (dextrose or saline)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8936445

Group type: EXPERIMENTAL
Intervention: Suboccipital manipulation (slow, steady, circular kneading)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Touching the suboccipital region (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Suboccipital manipulation
Number of subjects: 25
Study: 1609951

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diazepam 0.5 mg/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Midazolam 0.25 mg/kg
Number of subjects: 200
Study: 4082242

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg every 6 h (Phase B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg every 6 h (Phase C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Theophylline (5 mg/kg) (Phase A)
Number of subjects: 18
Study: 30261748

Group type: EXPERIMENTAL
Intervention: VacuMed® treatment thrice weekly for 6 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 48
Study: 29889382

Group type: EXPERIMENTAL
Intervention: UDCA monotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: UDCA + Hymecromone
Number of subjects: 42
Study: 24878521

Group type: EXPERIMENTAL
Intervention: E-health4Uth
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: E-health4Uth and consultation
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: E-health4Uth and consultation (subgroup at risk of mental health problems)
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 1256
Study: 22494671

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Number of subjects: 203
Study: 20598621

Group type: EXPERIMENTAL
Intervention: Baseline demographic parameters (education and age)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive measures (RBANS, FAB, Letter-Number Sequencing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of symptomatic therapy
Number of subjects: 0
Study: 18036365

Group type: EXPERIMENTAL
Intervention: 20 mg/day rosuvastatin
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802
Study: 16037102

Group type: EXPERIMENTAL
Intervention: LDL-cholesterol levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Negative remodelling (RI<1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Apolipoprotein-B levels
Number of subjects: 80
Study: 12447338

Group type: EXPERIMENTAL
Intervention: Hyperoxia with normocapnia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard oxygen treatment
Number of subjects: 14
Study: 10696278

Group type: EXPERIMENTAL
Intervention: Adapting subjects to an unambiguous version of the figure before presentation of the traditional reversible figure.
Number of subjects: 0
Study: 8623801

Group type: EXPERIMENTAL
Intervention: Oral micronized dehydroepiandrosterone 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral crystalline dehydroepiandrosterone 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vaginal micronized dehydroepiandrosterone 150 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral micronized dehydroepiandrosterone 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 1952858

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil at 250 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefaclor at 250 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cefaclor at 375 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily
Number of subjects: 24
Study: 7039204

Group type: EXPERIMENTAL
Intervention: Cimetidine (1.2 grams daily for 35 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31433518

Group type: EXPERIMENTAL
Intervention: Zoledronate (ZOL) 5 mg infusion
Number of subjects: 57

Group type: COMPARATOR
Intervention: Denosumab (Dmab) 60 mg injections (2 additional injections)
Number of subjects: 57
Study: 29970736

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (Group A) 1 mg/kg for two weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (Group B) 30 mg/kg for three days followed by oral prednisolone 1 mg/kg for two weeks
Number of subjects: 31
Study: 26829376

Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA)
Number of subjects: 10
Study: 24866862

Group type: EXPERIMENTAL
Intervention: Structured, moderate-intensity physical activity program (n=818)
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education program (n=817)
Number of subjects: 1635
Study: 22774791

Group type: EXPERIMENTAL
Intervention: Behavioral Methods/Homework
Number of subjects: 176

Group type: COMPARATOR
Intervention: Combined treatment (Cognitive Therapy + Antidepressant medication)
Number of subjects: 176
Study: 20716770

Group type: EXPERIMENTAL
Intervention: Zosuquidar (550 mg)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 17926625

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Western medicine (control)
Number of subjects: 11
Study: 16374982

Group type: EXPERIMENTAL
Intervention: General sites
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Specific non-commercial sites
Number of subjects: 253
Study: 12422079

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (ampicillin/sulbactam, 25 mg/kg/daily)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment combined with intranasal budesonide (200 mg/daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study: 11938741

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg administered intravenously)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no diazepam administered)
Number of subjects: 62
Study: 7583507

Group type: EXPERIMENTAL
Intervention: Female veterans with affective disorders and schizoaffective disorder
Number of subjects: 51

Group type: COMPARATOR
Intervention: Male veterans with anxiety disorders, schizophrenia, and substance use disorders
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Trauma history in female veterans
Number of subjects: 51

Group type: COMPARATOR
Intervention: Posttraumatic stress disorder diagnosis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Marital status
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Caretaking responsibilities
Number of subjects: 51
Study: 2046138

Group type: EXPERIMENTAL
Intervention: CV-4151 (selective inhibitor of thromboxane A2 synthetase), administered greater than or equal to 2 days before angioplasty and continued until follow-up (3-6 months after angioplasty)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 85
Study: 6459027

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ticarcillin plus amikacin
Number of subjects: 38
Study: 31085099

Group type: EXPERIMENTAL
Intervention: Hybrid presentations
Number of subjects: 166

Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 166
Study: 28650194

Group type: EXPERIMENTAL
Intervention: Internet-delivered parent-child interaction therapy (I-PCIT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: clinic-based parent-child interaction therapy (PCIT)
Number of subjects: 40
Study: 26076571

Group type: EXPERIMENTAL
Intervention: Chronic glucose metabolism disorders (A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 130
Study: 24289181

Group type: EXPERIMENTAL
Intervention: Management of atrial fibrillation (AF)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Coordination of primary and secondary care
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Patient engagement and support
Number of subjects: 1500
Study: 21550018

Group type: EXPERIMENTAL
Intervention: Adopting a distanced stance (third-person perspective)
Number of subjects: 0
Study: 19549020

Group type: EXPERIMENTAL
Intervention: 1,800 mg/d EPA-DHA (n=96)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 400 mg/d EPA-DHA (n=100)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo capsules (n=106)
Number of subjects: 302